Solara Active Pharma Sciences informs about press release

07 Aug 2023 Evaluate

Solara Active Pharma Sciences has informed that the company (Solara) has successfully completed the inspection carried out by the US Food and Drug Administration (US FDA or Agency) at its Cuddalore facility (Tamil Nadu). The Agency, with its designated investigators, inspected the Cuddalore facility between July 31, 2023 – August 04, 2023. The inspection established that the facility is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from the Agency. With this successful inspection outcome, the current inspection classification of Cuddalore site shall be reinstated to NAI (No Action Indicated). The Cuddalore API site is a multi-product facility, caters wide range of APIs to various regulated markets across the globe, including U.S., Europe, Japan and other markets. In this regard, the company has attached a press release.

The above information is a part of company’s filings submitted to BSE.

Solara Active Pharma Share Price

509.40 -24.55 (-4.60%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...